Use of a Treated, Devitalized and Sterile Umbilical Cord Amniotic Membrane in the Treatment of Trapeziometacarpal Osteoarthritis

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorTBF Genie Tissulaire

About this trial

The objective of this clinical trial is to evaluate whether a human umbilical cord amniotic membrane allograft can serve as an interposition implant in the surgical treatment of trapeziometacarpal osteoarthritis.

The main question this study aims to address is :

\- Can interposition of a human umbilical cord amniotic membrane within the trapeziometacarpal joint reduces postoperative pain and improves thumb mobility, grip and pinch strength, and overall wrist function.

Participant will:

* Undergo surgical treatment of the trapeziometacarpal osteoarthritis with the interposition in articular joint of an amniotic membrane of umbilical cord allograft on Day 0 * Visit the center for a series of tests 1 month, 3 months, 6 months and 12 months after the surgical intervention.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patient presenting with symptomatic osteoarthritis of the trapeziometacarpal joint, with wrist pain ≥ 40/100 according to the PRWE pain subscale (scaled to 100).

Patient who has received medical treatment for functional symptoms for more than 3 months without improvement, and for whom surgical intervention is indicated.

Patient with radiographic stage I-II trapeziometacarpal joint osteoarthritis according to the Eaton-Glickel classification.

Patient able to understand, date, and sign the informed consent form.

Disqualifiers

Pregnant or breastfeeding woman ; woman without effective contraception.

Patient with scaphotrapeziotrapezoid (STT) joint osteoarthritis requiring prosthetic surgical treatment.

Patient with thumb osteoarthritis secondary to a systemic inflammatory disease (e.g., rheumatoid arthritis).

Patient with osteoarthritis experiencing an acute inflammatory flare, characterized by a warm, painful, and swollen joint at the time of enrollment.

Trial design

Design model

Single group

Treatments tested in this trial

  • with SclerFIX

    Procedure/Surgery

    Use of the treated umbilical cord amniotic membrane allograft SclerFIX as an interposition implant in the TMC joint

Treatment groups

22 Participants
are divided into 1 treatment group
Group A: SclerFIXExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Change in thumb osteoarthritis-related pain between the baseline and the the 12-month end-of-study visit.

Thumb osteoarthritis-related pain will be assessed using the PRWE (Patient-Rated Wrist Evaluation) pain subscale and expressed as a percentage. The use of oral analgesics for hand pain will also be recorded at each follow-up visit, based on the preceding 7 days.

Time frame
Enrollment, 12 months

Secondary outcomes

1

Change in thumb mobility between the baseline and the post-operative visits.

Thumb mobility will be determined by the active range of motion of the TMC joint and by the active thumb opposition. Active range of motion of the TMC joint will be measured using goniometer. Active thumb opposition will be assessed according to the Kapandji score.

Time frame
Enrollment, 3 months, 6 months and 12 months
2

Change in the strength of the thumb between the baseline and the post-operative visits.

Pinch strength will be measured using a pinch gauge.

Time frame
Enrollment, 3 months, 6 months, 12 months
3

Change in the strength of the hand between the baseline and the post-operative visits.

Grip strength will be measured using a hand dynamometer.

Time frame
Enrollment, 3 months, 6 months, 12 months
4

Change in the daily functionality of the wrist between the baseline and the post-operative visits.

Daily functionality of the wrist will be assessed using the PRWE (Patient-Rated Wrist Evaluation) function subscale and expressed as a percentage.

Time frame
Enrollment, 3 months, 6 months, 12 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.